Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Common Equity (2016 - 2025)

Purple Biotech has reported Common Equity over the past 7 years, most recently at $47.1 million for Q4 2022.

  • Quarterly Common Equity fell 27.66% to $47.1 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $47.1 million through Dec 2022, down 27.66% year-over-year, with the annual reading at $47.1 million for FY2022, 27.66% down from the prior year.
  • Common Equity was $47.1 million for Q4 2022 at Purple Biotech, down from $51.9 million in the prior quarter.
  • Over five years, Common Equity peaked at $79.8 million in Q4 2020 and troughed at $10.1 million in Q2 2018.
  • The 5-year median for Common Equity is $55.6 million (2020), against an average of $48.0 million.
  • Year-over-year, Common Equity soared 634.43% in 2020 and then fell 27.66% in 2022.
  • A 5-year view of Common Equity shows it stood at $11.0 million in 2018, then decreased by 1.32% to $10.9 million in 2019, then soared by 634.43% to $79.8 million in 2020, then dropped by 18.36% to $65.1 million in 2021, then fell by 27.66% to $47.1 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Common Equity are $47.1 million (Q4 2022), $51.9 million (Q3 2022), and $55.4 million (Q2 2022).